I have no issue with the need for major pharma. At 9:45 tomorrow morning would be nice.
I also agree that market appreciation of a Chinese CHF partner will not happen until royalty payments commence.
Perhaps the market should read up. China is becoming the first release site of choice for many medicines developed by multinational pharma. Large market, one regulator, much easier than the EU where you still have to work with each state after EU approval.
As ever DYOR, not hard to find.
laughable, page-10
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.015(1.04%) |
Mkt cap ! $1.661B | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.46 | $1.40 | $3.815M | 2.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11031 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 14844 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |